EP0617621A4 - Central cholecystokinin antagonists having pharmaceutical activity. - Google Patents

Central cholecystokinin antagonists having pharmaceutical activity.

Info

Publication number: EP0617621A4
Authority: EP; European Patent Office
Prior art keywords: pharmaceutical activity; cholecystokinin antagonists; central; central cholecystokinin; antagonists
Prior art date: 1991-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP92903432A

Other languages

German (de)

French (fr)

Other versions

EP0617621A1 (en

Inventor

David Christopher Horwell

John Hughes

Geoff Neil Woodruff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Organon Pharma UK Ltd

Original Assignee

Merck Sharp and Dohme Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-20

Filing date

1991-12-20

Publication date

1995-04-05

1991-12-20 Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd

1991-12-20 Priority to EP96200242A priority Critical patent/EP0729752A2/en

1994-10-05 Publication of EP0617621A1 publication Critical patent/EP0617621A1/en

1995-04-05 Publication of EP0617621A4 publication Critical patent/EP0617621A4/en

Status Withdrawn legal-status Critical Current

Links

102100025841 Cholecystokinin Human genes 0.000 title 1
101800001982 Cholecystokinin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
229940107137 cholecystokinin Drugs 0.000 title 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

EP92903432A 1991-12-20 1991-12-20 Central cholecystokinin antagonists having pharmaceutical activity. Withdrawn EP0617621A4 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP96200242A EP0729752A2 (en)	1991-12-20	1991-12-20	Central cholecystokinin antagonists having pharmaceutical activity

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1991/009555 WO1993012791A1 (en)	1991-12-20	1991-12-20	Central cholecystokinin antagonists having pharmaceutical activity

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP96200242A Division EP0729752A2 (en)	1991-12-20	1991-12-20	Central cholecystokinin antagonists having pharmaceutical activity

Publications (2)

Publication Number	Publication Date
EP0617621A1 EP0617621A1 (en)	1994-10-05
EP0617621A4 true EP0617621A4 (en)	1995-04-05

Family

ID=22226062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP92903432A Withdrawn EP0617621A4 (en)	1991-12-20	1991-12-20	Central cholecystokinin antagonists having pharmaceutical activity.

Country Status (3)

Country	Link
EP (1)	EP0617621A4 (en)
JP (1)	JPH07507993A (en)
WO (1)	WO1993012791A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3457312B2 (en) *	1992-07-29	2003-10-14	メルクシヤープエンドドームリミテツド	Benzodiasepine derivative
FR2744363B1 (en) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	APPLICATION OF THIAZOLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIA OR EXCESSIVE USE
FR2744361B1 (en) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE
FR2744362B1 (en) *	1996-02-07	1998-02-27	Rhone Poulenc Rorer Sa	APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE
TW442449B (en)	1996-07-04	2001-06-23	Hoechst Ag	Process for preparing 1,2-dichloroethane by direct chlorination
WO2000073284A2 (en)	1999-05-26	2000-12-07	Du Pont Pharmaceuticals Company	1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
WO2007009691A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Combination of substituted pyrazolines and anti -addictive agent
EP1749525A1 (en) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Combination of substituted pyrazolines and anti-addictive agent
US8247438B2 (en)	2008-02-27	2012-08-21	Neuropill, Inc.	Methods for treating schizophrenia
WO2012075456A1 (en)	2010-12-02	2012-06-07	Constellation Pharmaceuticals	Bromodomain inhibitors and uses thereof
AR084070A1 (en)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	BROMODOMINIUM INHIBITORS AND USES OF THE SAME
EP2705039B1 (en)	2011-05-04	2017-07-26	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2012174487A2 (en)	2011-06-17	2012-12-20	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
EP2864336B1 (en)	2012-06-06	2016-11-23	Constellation Pharmaceuticals, Inc.	Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (en)	2012-06-06	2017-10-21	星宿藥物公司	Bromodomain inhibitors and uses thereof
ES2725928T3 (en)	2014-06-20	2019-09-30	Constellation Pharmaceuticals Inc	Crystal forms of 2 - ((4S) -6- (4-chlorophenyl) -1-methyl-4H-benzo [c] isoxazolo [4,5-e] azepin-4-yl) acetamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0411668A2 (en) *	1989-08-04	1991-02-06	MERCK SHARP & DOHME LTD.	Central cholecystokinin antagonists for treatment of psychiatric disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3663771A (en) *	1971-01-12	1972-05-16	Gulf & Western Industries	Distributor rotor with improved contact securing means
NZ212436A (en) *	1984-06-25	1989-04-26	Rotta Research Lab	D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
US4820834A (en) *	1984-06-26	1989-04-11	Merck & Co., Inc.	Benzodiazepine analogs
IT1215169B (en) *	1985-12-17	1990-01-31	Rotta Research Lab	OXYGENATED ALCHYL DERIVATIVES OF GLUTAMIC AND ASPARTIC ACIDS WITH ANTAGONIST ACTIVITY ON BIOACTIVE POLYPEPTIDES AND PROCEDURE FOR THEIR PREPARATION
CA2032427A1 (en) *	1989-12-18	1991-06-19	Mark G. Bock	Benzodiazepines analogs
CA2032226A1 (en) *	1989-12-18	1991-06-19	Mark G. Bock	Benzodiazepine analogs

1991
- 1991-12-20 EP EP92903432A patent/EP0617621A4/en not_active Withdrawn
- 1991-12-20 JP JP4503379A patent/JPH07507993A/en active Pending
- 1991-12-20 WO PCT/US1991/009555 patent/WO1993012791A1/en not_active Application Discontinuation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0411668A2 (en) *	1989-08-04	1991-02-06	MERCK SHARP & DOHME LTD.	Central cholecystokinin antagonists for treatment of psychiatric disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312791A1 *

Also Published As

Publication number	Publication date
EP0617621A1 (en)	1994-10-05
WO1993012791A1 (en)	1993-07-08
JPH07507993A (en)	1995-09-07

Legal Events

Date	Code	Title	Description
1994-08-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1994-10-05	17P	Request for examination filed	Effective date: 19940609
1994-10-05	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1995-04-05	A4	Supplementary search report drawn up and despatched	Effective date: 19950210
1995-04-05	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1998-08-12	17Q	First examination report despatched	Effective date: 19980630
1999-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
1999-05-06	18D	Application deemed to be withdrawn	Effective date: 19981111

Publication	Publication Date	Title
GR3018318T3 (en)	1996-03-31	Pharmaceutical agents.
PL297747A1 (en)	1993-11-02	Prolonged action pharmaceutical dosage forms
PH31205A (en)	1998-05-05	Pharmaceutical composition.
EP0670716A4 (en)	1996-10-02	Tastemasked pharmaceutical materials.
ZA926020B (en)	1993-03-10	Pharmaceutical combination formulation.
GR3036937T3 (en)	2002-01-31	Pharmaceutical formulations.
ZA92600B (en)	1992-10-28	Lhrh antagonists
GR3032366T3 (en)	2000-04-27	Pharmaceutical cyclosporin composition.
EP0673247A4 (en)	1996-05-01	Fibrinogen receptor antagonists.
EP0667773A4 (en)	1996-09-25	Fibrinogen receptor antagonists.
FI921060A0 (en)	1992-03-11	PHARMACEUTICAL AEROSOLFORMULERINGAR.
FI922252A0 (en)	1992-05-18	PHARMACEUTICAL SAMMANSAETTNING.
ZA927562B (en)	1993-04-14	Medicament.
PH31071A (en)	1998-02-05	Substituted pyrridopyrimidines useful antgiotensinII antagonists.
EP0617621A4 (en)	1995-04-05	Central cholecystokinin antagonists having pharmaceutical activity.
ZA9110018B (en)	1993-06-21	2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity.
OA09810A (en)	1994-04-15	Pharmaceutical composition.
ZA92110B (en)	1993-07-08	Pharmaceutical compositions.
GB9102727D0 (en)	1991-03-27	Pharmaceutical agent
ZA927506B (en)	1993-05-03	New drug formulation.
AU113462S (en)	1992-03-13	Dosage center
EP0600754A3 (en)	1995-05-24	Constant pharmaceutical infuser.
ZA927369B (en)	1993-06-18	Pharmaceutical compositions.
ZA939626B (en)	1994-08-18	Pharmaceutical compounds.
ZA922586B (en)	1993-03-31	Cholecystokinin antagonists